Karolinska Development AB is an investment company focused on identifying medical innovation and investing in the creation and growth of companies developing these assets into differentiated products that will make a difference to patients’ lives and provide an attractive return on investment.
Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.
Karolinska Development has established a portfolio of 10 companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.
The Company is led by a team including investment professionals with strong venture capital backgrounds, experienced company builders and entrepreneurs, with access to a strong global network.
For more information, please visit www.karolinskadevelopment.com
Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.
Karolinska Development has established a portfolio of 10 companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.
The Company is led by a team including investment professionals with strong venture capital backgrounds, experienced company builders and entrepreneurs, with access to a strong global network.
For more information, please visit www.karolinskadevelopment.com
Location: Sweden, Solna kommun
Employees: 1-10
Founded date: 2003
Investment Type: Venture Capital
Portfolio 9
| Date | Name | Website | Total Raised | Location |
| 29.03.2022 | AnaCardio | anacardio.com | $41.56M | Sweden, So... |
| - | OssDsign | ossdsign.com | $48.74M | Sweden, Up... |
| - | Umecrine C... | umecrinecognition.com | - | Burkina Fa... |
| - | Forendo Ph... | forendo.com | $13.93M | - |
| - | Dilafor AB | dilafor.com | - | - |
| - | Aprea | aprea.com | $114.76M | - |
| - | Biosergen ... | biosergen.se | - | - |
| - | Promimic | promimic.com | $1.54M | Sweden, Mö... |
| - | Modus Ther... | modustx.com | $23.13M | Sweden, St... |
Persons 11
| Date | First Name | Last Name | Title | Location | |||
| - | Eva | Montgomeri... | Head of Ac... | linkedin.c... | - | - | - |
| - | Viktor | Drvota | Chief Exec... | linkedin.c... | - | - | - |
| - | Johan | Dighed | Chief Lega... | - | - | - | |
| - | Mikaela | Sörman | Analyst | - | - | - | |
| - | Hans | Christophe... | Chief Fina... | - | - | - | |
| - | Elisabet | Gimbringer | Financial ... | - | - | - | |
| - | Yan | Cheng | President ... | - | - | - | |
| - | Linda | Spahiu Elv... | Investment... | - | - | - | |
| - | John | Öhd | Chief Scie... | - | - | - | |
| - | Linda | Spahiu | Investment... | - | - | - |
Show more
Mentions in press and media 9
| Date | Title | Description |
| 09.06.2025 | Revised proposal for election of the board of directors in OssDsign | Revised proposal for election of the board of directors in OssDsign Mon, Jun 09, 2025 14:00 CET Report this content Uppsala, June 9, 2025. OssDsign AB (publ.) today announces, through the nomination committee, a revised proposal for electio... |
| 11.01.2025 | AnaCardio's €19 Million Leap: A New Dawn for Heart Failure Treatment | In the world of biopharmaceuticals, every funding round can feel like a heartbeat—vital and pulsating with potential. AnaCardio, a clinical-stage startup based in Stockholm, has just secured €19 million (approximately USD 19 million) to adv... |
| 10.01.2025 | AnaCardio pumps €19 million into heart failure treatment innovation | AnaCardio, a clinical-stage biopharmaceutical startup headquartered in Stockholm, has secured €17.8 million in a Series A extension round to develop their drug candidate AC01. The financing was co-led by Novo Holdings, Pureos Bioventures, a... |
| 21.05.2021 | KAROLINSKA DEVELOPMENT AB (PUBL) Karolinska Development : portfolio company Umecrine Cognition initiates preparations for listing on Nasdaq First North Growth Market | STOCKHOLM, SWEDEN 21 May 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Umecrine Cognition is preparing a listing on Nasdaq First North Growth Market in Stockholm during the fourth quarte... |
| 22.04.2021 | KAROLINSKA DEVELOPMENT AB (PUBL) Karolinska Development : portfolio company Umecrine Cognition publishes clinical research results in a highly regarded journal | STOCKHOLM, SWEDEN 22 April 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Umecrine Cognition has published results from the recently conducted phase 2a study of the drug candidate golexan... |
| 28.04.2017 | Novartis vet named CMO at Rgenix; Ophthotech promotes Sblendorio to CEO spot | Harold “Barry” Selick → UCSF hired Harold “Barry” Sellick as its new vice chancellor to nurture inventions and bring new products to the market at a more advanced stage. And to that end he will supervise proof-of-concept stud... |
| 21.04.2017 | Celgene grabs more space in Cambridge; Karolinska Dev gets new CEO | → Fast-growing Celgene is expanding its footprint in Cambridge, MA, reports the Boston Business Journal, subletting 40,000 square feet of space that had been emptied after Amgen moved staff to a new facility on Kendall Squa... |
| 22.03.2017 | Neurocrine fleshes out its PhIII case for valbenazine; Avrobio adds to gene therapy pipeline | → Neurocrine has already posted the key late-stage data that it took to the FDA in building a case for Ingrezza (valbenazine) as a new therapy for tardive dyskinesia. But now it’s published the full set of data in its fav... |
| 29.06.2010 | Karolinska Development and Kurma Biofund Sign Strategic Agreement to Identify Life Science Oppurtunities in Europe | Karolinska Development AB, a Solna, Sweden-based life science investor, and Kurma Biofund, a venture capital fund based in Paris, France, have entered into a strategic partnership. The purpose of the deal is to identify early stage co-inves... |